Clinical impact of early progression among patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs) in first-line (1L) setting: IMPACT RCC real-world study.

被引：0
|
作者：
Hutson, Thomas E.
Liu, Frank Xiaoqing
Pandya, Shivani
Dieyi, Christopher
Kim, Ruth
Krulewicz, Stan
Kasturi, Vijay
Bhanegaonkar, Abhijeet
机构：
[1] Texas Oncol Sammons Canc Ctr, Dallas, TX USA
[2] EMD Serono Res & Dev Inst Inc, Rockland, MA USA
[3] STATinMED Res, Plano, TX USA
[4] Pfizer Inc, New York, NY USA
[5] Pfizer Inc, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17079
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Combination of immunotherapy and tyrosine kinase inhibitor in first-line metastatic renal cell carcinoma: A real-world Indian experience.
    Rauthan, Amit
    Patil, Poonam
    Murthy, Nitin Yashas
    Somashekhar, S. P.
    Zaveri, Shabber
    Aswath, Rajashri
    Prathyush, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.
    Heseltine, Jonathan
    Allison, Jennifer
    Wong, Sam
    Prasad, Kellati
    Wong, Helen
    Oong, Zhu
    Charnley, Natalie
    Law, Andrea
    Parikh, Omi
    Pillai, Manon Rhys
    Waddell, Tom
    Griffiths, Richard
    Chow, Shien
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [23] A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States
    Kolibaba, Kathryn
    Zhou, Jie
    Keating, Scott Justin
    Clark, Jamyia
    Brokars, John
    Kee, Arianna
    Copher, Ronda
    Stwalley, Brian
    Jabbour, Elias
    [J]. BLOOD, 2020, 136
  • [24] First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.
    D'Angelo, Sandra P.
    Russell, Jeffrey
    Hassel, Jessica Cecile
    Lebbe, Celeste
    Chmielowski, Bartosz
    Rabinowits, Guilherme
    Terheyden, Patrick
    Brownell, Isaac
    Zwiener, Isabella
    Bajars, Marcis
    Hennessy, Meliessa
    Kaufman, Howard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) -based regimens.
    Eid, Marc
    Labaki, Chris
    Semaan, Karl
    Saliby, Renee Maria
    Saad, Eddy
    Shah, Valisha
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES
    Mhatre, S.
    Lin, S.
    Surinach, A.
    Vohra, R.
    Satram-Hoang, S.
    Simpson, J.
    Wallen, H.
    Ogale, S.
    Gong, J.
    Pal, S. K.
    George, D. J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A755 - A755
  • [27] Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors
    Omae, Kenji
    Fukuma, Shingo
    Ikenoue, Tatsuyoshi
    Kondo, Tsunenori
    Takagi, Toshio
    Ishihara, Hiroki
    Tanabe, Kazunari
    Fukuhara, Shunichi
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (09) : 540.e7 - 540.e12
  • [28] Effect of ABO blood type on the outcomes of metastatic renal cell carcinoma patients treated with first-line tyrosine kinase inhibitors
    Omae, Kenji
    Fukuma, Shingo
    Ikenoue, Tatsuyoshi
    Kondo, Tsunenori
    Takagi, Toshio
    Ishihara, Hiroki
    Tanabe, Kazunari
    Fukuhara, Shunichi
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 391 - 391
  • [29] Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
    Fiala, Ondrej
    Buti, Sebastiano
    Bamias, Aristotelis
    Massari, Francesco
    Pichler, Renate
    Maruzzo, Marco
    Grande, Enrique
    De Giorgi, Ugo
    Molina-Cerrillo, Javier
    Seront, Emmanuel
    Calabro, Fabio
    Myint, Zin W.
    Facchini, Gaetano
    Kopp, Ray Manneh
    Berardi, Rossana
    Kucharz, Jakub
    Vitale, Maria Giuseppa
    Pinto, Alvaro
    Formisano, Luigi
    Buettner, Thomas
    Messina, Carlo
    Monteiro, Fernando Sabino M.
    Battelli, Nicola
    Kanesvaran, Ravindran
    Buchler, Tomas
    Kopecky, Jindrich
    Santini, Daniele
    Giudice, Giulia Claire
    Porta, Camillo
    Santoni, Matteo
    [J]. TARGETED ONCOLOGY, 2024, 19 (04) : 587 - 599
  • [30] Incidence and severity of hypothyroidism and survival outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs).
    Bailey, Erin B.
    Tantravahi, Srinivas Kiran
    Wells, Chesley E.
    Straubhar, Alli M.
    Batten, Julia A.
    Poole, Austin
    Stenehjem, David D.
    Agarwal, Neeraj
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345